169 related articles for article (PubMed ID: 35169388)
1. Update Breast Cancer 2021 Part 4 - Prevention and Early Stages.
Thomssen C; Fehm TN; Stickeler E; Fasching PA; Janni W; Kolberg-Liedtke C; Kolberg HC; Lüftner D; Müller V; Schütz F; Belleville E; Bader S; Untch M; Welslau M; Thill M; Hartkopf AD; Tesch H; Ditsch N; Lux MP; Wöckel A; Aktas B; Schneeweiss A; Würstlein R
Geburtshilfe Frauenheilkd; 2022 Feb; 82(2):206-214. PubMed ID: 35169388
[TBL] [Abstract][Full Text] [Related]
2. Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights.
Lucas MW; Kelly CM
Cancer Manag Res; 2022; 14():2493-2506. PubMed ID: 35999966
[TBL] [Abstract][Full Text] [Related]
3. PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
Gonçalves A; Bertucci A; Bertucci F
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32471249
[TBL] [Abstract][Full Text] [Related]
4. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
5. Emerging Targeted Therapies for Early Breast Cancer.
Schlam I; Tarantino P; Morganti S; Lynce F; Trapani D; Mayer EL; Garrido-Castro AC; Waks A; Tolaney SM
Drugs; 2022 Sep; 82(14):1437-1451. PubMed ID: 36207645
[TBL] [Abstract][Full Text] [Related]
6. Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic
Schwartzberg LS; Kiedrowski LA
Ther Adv Med Oncol; 2021; 13():17588359211006962. PubMed ID: 33868464
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
Clifton K; Gutierrez-Barrera A; Ma J; Bassett R; Litton J; Kuerer H; Moulder S; Albarracin C; Hortobagyi G; Arun B
Breast Cancer Res Treat; 2018 Jul; 170(1):101-109. PubMed ID: 29470805
[TBL] [Abstract][Full Text] [Related]
8. Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives.
Barchiesi G; Roberto M; Verrico M; Vici P; Tomao S; Tomao F
Front Oncol; 2021; 11():769280. PubMed ID: 34900718
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline
Litton JK; Scoggins ME; Hess KR; Adrada BE; Murthy RK; Damodaran S; DeSnyder SM; Brewster AM; Barcenas CH; Valero V; Whitman GJ; Schwartz-Gomez J; Mittendorf EA; Thompson AM; Helgason T; Ibrahim N; Piwnica-Worms H; Moulder SL; Arun BK
J Clin Oncol; 2020 Feb; 38(5):388-394. PubMed ID: 31461380
[TBL] [Abstract][Full Text] [Related]
11. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
[TBL] [Abstract][Full Text] [Related]
12. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
13. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
[TBL] [Abstract][Full Text] [Related]
14. A review of current progress in triple-negative breast cancer therapy.
Shen M; Pan H; Chen Y; Xu YH; Yang W; Wu Z
Open Med (Wars); 2020; 15(1):1143-1149. PubMed ID: 33336070
[TBL] [Abstract][Full Text] [Related]
15. Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer.
Garber HR; Litton JK
Curr Opin Oncol; 2019 May; 31(3):247-255. PubMed ID: 30789866
[TBL] [Abstract][Full Text] [Related]
16. ASCO 2017: highlights in breast cancer.
Bartsch R; Bergen E
Memo; 2017; 10(4):228-232. PubMed ID: 29250202
[TBL] [Abstract][Full Text] [Related]
17. The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.
Pop L; Suciu I; Ionescu O; Bacalbasa N; Ionescu P
J Med Life; 2021; 14(1):17-20. PubMed ID: 33767780
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
19. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
20. Pembrolizumab and atezolizumab in triple-negative breast cancer.
Kwapisz D
Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]